Skip to Main Content


Skip Nav Destination
Issue Cover
Current Issue
Volume 141,
Issue 5,
February 2 2023

Issue Highlights

Latest in Blood
Free Articles
Plenary Papers
Johannes Schmoellerl; Inês A.M. Barbosa; Martina Minnich; Florian Andersch; Leonie Smeenk; Marije Havermans; Thomas Eder; Tobias Neumann; Julian Jude; Michaela Fellner; Anja Ebert; Monika Steininger; Ruud Delwel; Florian Grebien; Johannes Zuber
DOI: 10.1182/blood.2022016592
First Edition
Maria-Riera Piqué-Borràs; Zivojin Jevtic; Frederik Otzen Bagger; Jonathan Seguin; Rathick Sivalingam; Matheus Filgueira Bezerra; Amber Louwaige; Sabine Juge; Ioannis Nellas; Robert Ivanek; Alexandar Tzankov; Ute Moll; Oriano Valerio Cantillo; Ramona Schultz-Heddergott; Alexandre Fagnan; Thomas Mercher; Juerg Schwaller
DOI: 10.1182/blood.2022017273
Clinical Trials and Observations
Lynn Daniel Malec; An Van Damme; Anthony KC Chan; Mariya Spasova; Nisha Jain; Charlotte Sensinger; Jennifer Dumont; Stefan Lethagen; Manuel Carcao; Flora Peyvandi
DOI: 10.1182/blood.2022017780


Featured Content

Itacitinib monotherapy for GVHD, the role of ERG in EVI1-driven AML, and germline DDX41 mutations in myeloid neoplasms

In this week's episode, we’ll discuss the safety and efficacy of itacitinib monotherapy in low-risk acute GVHD, learn how ERG was discovered to be a key transcriptional target in EVI1-driven AML, and define a unique subtype of myeloid neoplasms characterized by germline DDX41 mutations.

EVI1 drives leukemogenesis through aberrant ERG activation

EVI1-rearranged acute myeloid leukemia is an aggressive malignancy associated with chemotherapy resistance and poor prognosis. In this Plenary Paper, Schmoellerl and colleagues used both human and murine models and genome-wide CRISPR screens to characterize the downstream targets of EVI1. They identified ERG as a direct transcriptional target of EVI1 that blocks differentiation and facilitates self-renewal, suggesting a regulatory pathway potentially useful for targeted therapy.

Effective treatment of low-risk acute GVHD with itacitinib monotherapy

Primary therapy for acute graft vs host disease (aGVHD) is systemic corticosteroids. Etra et al report on the results of a nonrandomized study of monotherapy with the selective JAK1 inhibitor itacitinib in 70 patients with low-risk aGVHD, compared to a contemporaneous cohort of steroid-treated patients. Responses to itacitinib were comparable to steroids (89% vs 86% at 28 days), with fewer serious viral and fungal infections with itacitinib, providing support for a randomized clinical trial in low-risk GVHD.

Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease that is supported by the tumor microenvironment. Cappelli and colleagues used primary T-ALL patient cells cocultured with endothelial cells (ECs) to delineate the role of ECs in chemoprotection of T-ALL cells and to screen for drugs to overcome that resistance. The authors identified 5 agents that improve survival in mouse xenografts, suggesting that the platform can be used to identify compounds that target tumor cell–EC interactions.

Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL

Two articles focus on the use of next generation sequencing (NGS) for the assessment of minimal residual disease (MRD). In the first article, Hengeveld et al report on a novel, academically developed immunoglobulin sequence-based NGS assay for quantitative detection of MRD in chronic lymphocytic leukemia (CLL). This technique, made available to other laboratories, has a range of detection that is more sensitive than conventional techniques and provides accurate prognostic stratification of patients with CLL. In the second article, Svaton et al compared allele-specific oligonucleotide polymerase chain reaction to NGS assay of immunoglobulin or T-cell receptor markers in pediatric B-cell acute lymphoblastic leukemia (ALL), again confirming that this is a reliable alternative for assessing MRD.

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Makishima and colleagues report on a comprehensive characterization of 346 patients with myeloid neoplasms (MN) in the context of germ line DDX41 mutation and 525 first-degree relatives. Development of MN increased rapidly after age 40, with 49% developing MN by age 90. Computations were different from DDX41 wild-type patients, and when present, did not worsen the prognosis associated with this subset of MN.

Close Modal

or Create an Account

Close Modal
Close Modal